Skip to main content
See every side of every news story
Published • loading... • Updated

Madrigal Turns Profitable as Rezdiffra Sales Surge 50%

Summary by MyChesCo
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) reported its first profitable quarter as sales of its liver disease treatment Rezdiffra rose 50% to $431.3 million in the third quarter …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MyChesCo broke the news on Tuesday, November 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal